TriangleHEALTH PROFESSIONAL · SOURCE READING
Targeted therapy
Source: Childhood Salivary Gland Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 23, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Salivary Gland Tumors / Treatment of Childhood Salivary Gland Tumors
Objective responses have been observed in all reported patients with recurrent NTRK fusion–positive MASC who were treated with entrectinib or larotrectinib.[36,37] Ten of 11 adolescent or adult patients with TRK fusion–positive salivary gland tumors who were treated with larotrectinib experienced partial or complete responses.[37]
For more information, see Salivary Gland Cancer Treatment.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice